Clinical trials
Completed Multiple Sclerosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,743 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 14 |
| 2002 | 19 |
| 2003 | 24 |
| 2004 | 27 |
| 2005 | 35 |
| 2006 | 51 |
| 2007 | 49 |
| 2008 | 51 |
| 2009 | 53 |
| 2010 | 70 |
| 2011 | 70 |
| 2012 | 82 |
| 2013 | 90 |
| 2014 | 98 |
| 2015 | 88 |
| 2016 | 74 |
| 2017 | 89 |
| 2018 | 117 |
| 2019 | 115 |
| 2020 | 108 |
| 2021 | 118 |
| 2022 | 83 |
| 2023 | 94 |
| 2024 | 51 |
| 2025 | 38 |
| 2026 | 12 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 1,743 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Biogen | 93 |
| Novartis Pharmaceuticals | 45 |
| Merck KGaA, Darmstadt, Germany | 35 |
| Bayer | 33 |
| Hasselt University | 28 |
| Gazi University | 26 |
| Sanofi | 22 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 20 |
| University of Washington | 18 |
| Kessler Foundation | 17 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 1,743 |
| Multiple Sclerosis, Relapsing-Remitting | 179 |
| Fatigue | 117 |
| Multiple Sclerosis, Chronic Progressive | 60 |
| Stroke | 46 |
| Spinal Cord Injuries | 44 |
| Muscle Spasticity | 37 |
| Recurrence | 36 |
| Autoimmune Diseases | 33 |
| Demyelinating Diseases | 32 |
Trials
Showing 1 to 25 of 1,743. Each trial links to its page on Pharma Observatory.
1,643 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.